G

GSK

Develops medicines, vaccines, and consumer health

ViiV Healthcare - Gsk, Head of Data and Technology Strategy

Full-Time
No salary listed
Expert
Master's, MBA, PharmD, PhD
Durham, NC, USA
HybridDomestic relocation package may be considered.
Business & StrategyCorporate Strategy

About the job

Requirements
  • A Master’s degree in Life Sciences, Data Science, Computer Science, Engineering, or Information Technology.
  • At least 12 years of experience in pharmaceutical, biotechnology, healthcare technology, or life-sciences consulting.
  • Experience in pharmaceutical research and development and applying data, digital platforms, analytics, artificial intelligence, and automation across scientific and development workflows.
  • Experience defining and executing enterprise or business-unit data, digital, technology, or artificial intelligence strategies and multi-year investment plans.
  • Experience translating business and scientific priorities into investment choices, prioritization decisions, and measurable outcomes.
  • Experience collaborating with technology functions to ensure products and programs reflect technical feasibility.
  • Experience prioritizing a portfolio under funding and capacity constraints, including deprioritizing and stopping work.
  • Experience leading cross-functional initiatives across business, scientific, data, and technology organizations in a global matrix.
  • Experience working with senior stakeholders, establishing governance and decision rights, and mobilizing partners without relying on direct authority.
  • Experience making build, buy, or partner decisions.
  • Experience assessing risks and balancing innovation, pace, value, feasibility, and control requirements.
  • Experience communicating scientific and technical concepts through decisions, actions, and executive communications.
  • Experience building teams and developing capabilities across direct reports and matrixed networks.
Responsibilities
  • Set, review, and own prioritization of the ViiV R&D data, technology, artificial intelligence, and automation portfolio, including confirming which demands proceed to assessment.
  • Lead development and execution of an integrated ViiV R&D capability, portfolio, and investment strategy for data, technology, artificial intelligence, and automation, aligned with scientific, portfolio, and business priorities and developed in formal partnership with ViiV Digital & Technology.
  • Translate R&D priorities into a sequenced, multi-year capability and investment roadmap covering business outcomes, milestones, funding needs, dependencies, named business owners, adoption expectations, and measures of success; partner with ViiV Digital & Technology to translate this into the technology roadmap, technical dependencies, and delivery sequence.
  • Partner with R&D leaders to identify and prioritize opportunities across Discovery, Development, Regulatory, CMC, Data & AI, and operational processes where technology can improve speed, quality, productivity, or decision-making.
  • Provide strategic sponsorship and integrated portfolio oversight for the R&D technology portfolio, including prioritization, leadership engagement, investment recommendations, value realization, and escalation of material risks or delivery issues, while ViiV Digital & Technology remains accountable for the technology roadmap and delivery sequencing.
  • Represent and advocate for ViiV R&D at portfolio and sponsorship level within GSK R&D technology strategy, governance, and platform investment, ensuring alignment between enterprise roadmaps and critical ViiV milestones.
  • Align governance and decision rights across ViiV R&D, ViiV Digital & Technology, GSK R&D, and GSK R&D Technology, including pathways for demand identification, prioritization, funding, delivery, adoption, and value realization.
  • Decide build, buy, partner, or fast-follow pathways based on a jointly governed evaluation informed by recommendations and input from ViiV Digital & Technology and Procurement partners.
  • Secure and allocate funding for the R&D technology portfolio, including GSK investment decisions, ViiV funding decisions, and negotiation, review, and renewal of ViiV-funded ring-fenced capacity within GSK.
  • Define the R&D data strategy and business priorities required to improve access to trusted, contextualized, and reusable data for scientific insight, analytics, artificial intelligence, and portfolio decision-making; own ontology creation, data acquisition priorities, and knowledge graph requirements that connect R&D data across the discovery-to-development lifecycle.
  • Ensure responsible application of artificial intelligence and advanced analytics across R&D, requiring clear intended use, scientific and business value, named business ownership, human oversight, data requirements, monitoring, traceability, and escalation; partner with accountable technology, privacy, legal, compliance, cybersecurity, GxP, and Responsible AI teams to apply appropriate governance and controls.
  • Be accountable for process redesign, adoption, and digital fluency across R&D, delivered through a dedicated internal team and a network of champions across R&D, so new capabilities are embedded into ways of working and deliver measurable, sustained outcomes.
  • Develop KPIs, scorecards, and value-realization measures to track portfolio progress, technology delivery progress, adoption, benefits, risks, and strategic alignment; lead regular reviews that support acceleration, continuation, re-scoping, deprioritization, or stopping decisions; and provide clear updates to the R&D Leadership Team.
  • Build productive partnerships with internal technology organizations, CROs, external providers, biotechnology companies, and academic collaborators to understand market capabilities, assess options, and accelerate strategic priorities, in coordination with ViiV Digital & Technology and Procurement.
  • Lead, develop, and inspire a high-performing, lean team and matrixed network capable of combining scientific understanding, technology strategy, portfolio thinking, and execution discipline.
  • Create clear communications explaining the R&D data and technology strategy, priorities, choices, and value to senior internal and external stakeholders.
Desired Qualifications
  • A PhD, PharmD, MBA, or equivalent advanced degree.
  • Strategic or management consultancy experience.
  • Deep knowledge of data platforms, scientific computing, advanced analytics, machine learning, generative artificial intelligence, and emerging R&D technologies.
  • Experience implementing technology governance in regulated environments, including collaboration with technology, cybersecurity, privacy, GxP, and Responsible AI functions.
  • Experience operating within a shared-services or vendor model in which core technology is provided by a parent or partner organization.
  • Experience in virology, immunology, translational research, or clinical development.
  • Experience managing strategic external technology partnerships, vendors, or alternative delivery models.
  • Experience developing investment cases, portfolio scenarios, KPIs, and benefits-realization frameworks for technology-enabled transformation.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Sharecast
Oct 19th, 2026
GSK's Ris-Rez shows 61pc response rate in early lung cancer study.

GSK's Ris-Rez shows 61pc response rate in early lung cancer study. 1,856.00p. 13:24 19/10/26. Drugmaker GSK reported new early-stage global data for risvutatug rezetecan (Ris-Rez), an experimental cancer treatment being tested in patients with relapsed small-cell lung cancer. 10,747.73. 5,853.07. 5,792.15. 24,009.43. 13:23 19/10/26. In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg. GSK said the results, which will be presented at the ESMO 2026 congress in Madrid, support using the 8mg/kg dose in its ongoing global phase III trial. The FTSE 100-listed company said the treatment's side-effect profile was manageable, with most issues linked to blood-related conditions. More serious side effects occurred in 42% of patients at the higher dose and 15% at the lower dose. One case of interstitial lung disease was reported across 50 patients. GSK's Hesham Abdullah said: "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options." As of 0905 BST, GSK shares were up 0.16% at 1,865.50p. Reporting by Iain Gilbert at Sharecast.com

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.